Predict-TB and Critical Path Institute: A Partnership to Develop Effective Treatment of Tuberculosis

Two public-private partnerships from the United States and the European Union collaborate to bring resources and talent together to fight one of the world’s deadliest diseases.

Predict-TB and Critical Path Institute: A Partnership to Develop Effective Treatment of Tuberculosis

The PreDiCT-TB consortium and the Critical Path to TB Drug Regimens (CPTR) have signed a memorandum of understanding to coordinate the work in developing new and effective treatment regimens for tuberculosis (TB). This was facilitated by two of the world’s leading organizations advancing scientific breakthroughs that help accelerate drug approvals, the Innovative Medicines Initiative (IMI) and Critical Path Institute (C-Path).

TB remains one of the leading causes of death worldwide. Nearly nine million new cases of TB and 1.4 million deaths are reported each year. Standard TB treatment takes months with a multi-drug regimen, while treating drug-resistant strains—which are on the rise globally—may take two years.

PreDiCT-TB is a public-private partnership funded by the EU Innovative Medicines Initiative, comprising three major pharmaceutical partners (GSK, Sanofi, and Janssen), two biotechnology firms (ZF Screens and Microsens Medtech) and fifteen academic partners headed by the University of Liverpool. The multidisciplinary consortium brings together experts in microbiology, pharmacology, engineering, mathematical modelling, and clinical trials to create a new integrated framework for TB drug development, making optimal use of preclinical information to design the most efficient clinical trials.


  • GlaxoSmithKline (GSK)

    Goods Supplier
    United Kingdom | Staff size: 10,000+

    We are a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Our products are used by millions of people around the world,...

  • Janssen

    United States | Staff size: 10,000+

    Janssen Research & Development, LLC, is united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important...

  • Sanofi

    Goods Supplier
    Canada | Staff size: Unknown

    Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales. Sanofi engages in the research and development,...

  • Bill & Melinda Gates Foundation (B&MGF)

    United States | Staff size: Unknown
    They are focused on the areas of greatest need, on the ways in which they can do the most good.


  • Critical Path Institute

    United States | Staff size: 26-50

    Critical Path Institute (C-Path) is a nonprofit, public-private partnership with the Food and Drug Administration (FDA) created under the auspices of the FDA’s Critical Path Initiative...

  • Global Alliance for TB Drug Development (TB Alliance)

    Advocacy NGO
    United States | Staff size: 26-50

    The Global Alliance for TB Drug Development (TB Alliance) is a not-for-profit, product development partnership accelerating the discovery and development of new tuberculosis (TB) drugs that will...

More Resources

Key Information

  • Start Date 2013